469 related articles for article (PubMed ID: 25223699)
1. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.
McCormack SA; Best BM
Clin Pharmacokinet; 2014 Nov; 53(11):989-1004. PubMed ID: 25223699
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.
Roustit M; Jlaiel M; Leclercq P; Stanke-Labesque F
Br J Clin Pharmacol; 2008 Aug; 66(2):179-95. PubMed ID: 18537960
[TBL] [Abstract][Full Text] [Related]
5. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Gingelmaier A; Kurowski M; Kästner R; Eberle J; Mylonas I; Belohradsky BH; Friese K; Grubert TA
AIDS; 2006 Aug; 20(13):1737-43. PubMed ID: 16931938
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of antiretrovirals in pregnant women.
Mirochnick M; Capparelli E
Clin Pharmacokinet; 2004; 43(15):1071-87. PubMed ID: 15568888
[TBL] [Abstract][Full Text] [Related]
7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
8. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
10. Transfer of antivirals across the human placenta.
Pacifici GM
Early Hum Dev; 2005 Aug; 81(8):647-54. PubMed ID: 15946808
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.
; Boyd MA; Kumarasamy N; Moore CL; Nwizu C; Losso MH; Mohapi L; Martin A; Kerr S; Sohn AH; Teppler H; Van de Steen O; Molina JM; Emery S; Cooper DA
Lancet; 2013 Jun; 381(9883):2091-9. PubMed ID: 23769235
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral medications during pregnancy for therapy or prophylaxis.
Stek AM
Curr HIV/AIDS Rep; 2009 May; 6(2):68-76. PubMed ID: 19358777
[TBL] [Abstract][Full Text] [Related]
13. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological considerations on the use of antiretrovirals in pregnancy.
Colbers A; Greupink R; Burger D
Curr Opin Infect Dis; 2013 Dec; 26(6):575-88. PubMed ID: 24152762
[TBL] [Abstract][Full Text] [Related]
15. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral pharmacology in pregnant women and their newborns.
Mirochnick M
Ann N Y Acad Sci; 2000 Nov; 918():287-97. PubMed ID: 11131716
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV.
Hodel EM; Marzolini C; Waitt C; Rakhmanina N
Curr Pharm Des; 2019; 25(5):556-576. PubMed ID: 30894103
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
19. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
Maliakkal A; Walmsley S; Tseng A
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
[TBL] [Abstract][Full Text] [Related]
20. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
